MFN2 and Insulin resistance: In a rat model of insulin resistance and obesity, empagliflozin regulates mitochondrial dynamics, increasing fusion protein mitofusin-2 (MFN2) expression, while decreasing the levels of the fission protein dynamin-related protein 1 (DRP1) in white adipose tissue [120].